Polycythemia Vera News and Research

RSS

Novel treatment for polycythemia vera shows promise in clinical trial

A novel treatment for polycythemia vera, a potentially fatal blood cancer, demonstrated the ability to control overproduction of red blood cells, the hallmark of this malignancy and many of its debilitating symptoms in a multi-center clinical trial led by the Icahn School of Medicine at Mount Sinai.

21 Feb 2024

Adoption of Mediterranean diet shows promise in easing symptoms for myeloproliferative neoplasm patients

Researchers assess the feasibility of an education-focused Mediterranean diet intervention among myeloproliferative neoplasm patients.

25 May 2023

Fatigue is common among older adults, and it has many possible causes

Nothing prepared Linda C. Johnson of Indianapolis for the fatigue that descended on her after a diagnosis of stage 4 lung cancer in early 2020.

4 Apr 2023

Researchers discover a novel signaling pathway that defines interferon responses in blood cancers

Northwestern Medicine investigators have discovered a novel signaling pathway activated by interferons, a group of immune system proteins, that suppresses the anti-tumor response of interferons in patients with a particular type of blood cancer, according to findings published in Nature Communications.

19 Apr 2022

Personalized determination of genetic factors may improve treatment for polycythaemia vera

Polycythaemia vera is a chronic malignant disease of the haematopoietic system and is treated with interferon-alpha-based drugs, in most cases with long-lasting success. However, in some cases this therapy is unsuccessful for reasons that are not yet understood.

8 Sep 2020

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.

31 May 2020

Popular cancer drug linked to weight gain and increased systolic blood pressure

Study: More than 300 million people affected worldwide by rare diseases

Rare diseases represent a global problem. Until now, the lack of data made it difficult to estimate their prevalence.

24 Oct 2019

FDA approves new drug to treat patients with myelofibrosis

Today, the U.S. Food and Drug Administration approved Inrebic (fedratinib) capsules to treat adult patients with certain types of myelofibrosis.

18 Aug 2019

People who have a parent, sibling, or child with blood cancer have higher risk of disease

New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with the disease.

9 Aug 2019

Potential combination therapy against rare disease of the bone marrow could improve treatment

Myelofibrosis is a severe and very rare hematological disease for which treatment has only been partially effective to date. Its low incidence rate is one of the reasons why effective therapies are still lacking.

19 Dec 2018

Researchers find STAT3 as therapeutic target for chronic active EBV infection

Tokyo Medical and Dental University study shows that ruxolitinib-induced inhibition of STAT3 activity blocks survival and reduces pro-inflammatory cytokine production in Epstein-Barr virus (EBV)-infected clonally proliferating T- or NK-cells in Chronic active Epstein-Barr virus infection.

20 Aug 2018

Detailed structure of protein pair offers blueprint for new medicines

Walter and Eliza Hall Institute researchers have visualized for the first time how the protein SOCS1 'switches off' cell signaling to dampen immune responses and block cancer growth.

4 Jun 2018

Sheffield scientists discover that simple arthritis drug could help treat blood cancer sufferers

Blood cancer sufferers could be treated with a simple arthritis drug, scientists at the University of Sheffield have discovered.

3 Aug 2017

Study finds new therapeutic target to prevent progression of rare blood cancer

In a laboratory study, Upstate Medical University researcher Golam Mohi, Ph.D., his graduate student Yue Yang, and colleagues, have found that the loss of gene EZH2 promotes the development of Myelofibrosis (MF) in mice.

7 Oct 2016

New NCCN Guidelines outline diagnosis, treatment strategies for myeloproliferative neoplasms

Myeloproliferative Neoplasms (MPN) are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia.

26 Sep 2016

Minihepcidins may potentially treat serious genetic blood diseases in children, adults

New research suggests that synthetic peptides called minihepcidins may potentially treat two serious genetic blood diseases in children and adults. Although those diseases, beta-thalassemia and polycythemia vera, have opposite effects on red blood cell production, treating animals with minihepcidin helps to restore normal levels of red blood cells and reduces spleen enlargement. It also controls the accumulation of excess levels of iron in beta-thalassemia that often causes severe toxic effects.

9 May 2016

Penn study forms basis for new treatment approaches for Sezary syndrome

Sezary syndrome (SS), an aggressive leukemia of mature T cells, is more complicated at a molecular level than ever suspected, according to investigators from the Perelman School of Medicine at the University of Pennsylvania.

8 Oct 2015

Three researchers recognised for their contributions to Australian medical research

Three top Walter and Eliza Hall Institute researchers have been recognised for their contributions to Australian medical research, with their election as fellows of the Australian Academy of Health and Medical Sciences.

7 Oct 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015